Cohance Lifesciences Ltd (COHANCE) — shareholding pattern, promoter holding, financials and share price
About Cohance Lifesciences Ltd (COHANCE)
Cohance Lifesciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as COHANCE and on the BSE under scrip code 543064. Its ISIN is INE03QK01018.
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations. [1]
Cohance Lifesciences is an integrated CDMO providing custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs, formulated drugs, ADC payloads and oligonucleotide building blocks for global pharma, biotech and specialty-chemical innovators, with manufacturing and R&D facilities across India and a presence in New Jersey supporting advanced modalities.
The company is in a transition phase with FY26 impacted by customer-led de-stocking and timing shifts, leading to an early-to-mid double-digit revenue decline guidance while management expects recovery and return to growth in FY27 as Phase III and commercial programmes convert for Cohance Lifesciences.
Listed peers in Pharmaceuticals: ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd, OneSource Specialty Pharma Ltd, Natco Pharma Ltd, Alembic Pharmaceuticals Ltd, Jubilant Pharmova Ltd.
Valuation & Returns
10 Jul 2026At ₹451.2 a share on 10 Jul 2026, Cohance Lifesciences Ltd (COHANCE) was valued at a price-to-earnings ratio of 114.98x against an industry P/E of 36.41x and a price-to-book of 10.17x on a book value of ₹44.35 per share as of Mar 2025. Solomo computes return on equity of 8.85% and return on capital employed of 12.36% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 114.98x
- Industry P/E
- 36.41x
- P/B
- 10.17x
- EPS (TTM)
- ₹3.92
- Book value / share
- ₹44.35
- ROE
- 8.85%
- ROCE
- 12.36%
- ROA
- 4.95%
- Debt / equity
- 0.16x
- Dividend yield
- 0%
- EBITDA margin
- 19.03%
- 52-week range
- ₹267.85 – ₹1,121.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Cohance Lifesciences Ltd (COHANCE) reported revenue of ₹2,269 crore, net profit of ₹150 crore and earnings per share of ₹4.68. That compares with revenue of ₹1,198 crore and net profit of ₹265 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹619.12 crore and net profit ₹8.31 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 |
| Net profit (₹ cr) | 454 | 411 | 300 | 265 | 150 |
| EPS (₹) | 17.83 | 16.16 | 11.8 | 10.52 | 4.68 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 5.57% | -6.09% | 13.91% |
| Profit growth | 0.12% | -21.33% | -11.83% |
| Stock price CAGR | -1% | -3% | -58% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 57.49% of Cohance Lifesciences Ltd (COHANCE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 6.5% and domestic institutional investors (DII) hold 20.09%. Promoters have pledged 94.6% of their holding. Market capitalisation was ₹17,261 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2020.
Largest disclosed public shareholders in Jun 2026: DSP REGULAR SAVINGS FUND 4.28%, ICIC PREDUENTIAL HEALTH CARE AND DIAGANOSTIC 4.19%, JASUB PROPERTY HOLDINGS LLP 3.84%, SBI MNC FUND 3.33%, JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED 2.51%, HDFC TRUSTEE COMPANY LIMITED - HDFC TAX SAVER FUND 2.16%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 57.49% | 94.6% | 6.5% | 20.09% | 42.51% |
| Mar 2026 | 57.49% | - | 5.59% | 21.79% | 42.51% |
| Dec 2025 | 57.49% | - | 6.02% | 21.57% | 42.51% |
| Sep 2025 | 57.49% | - | 6.51% | 20.82% | 42.51% |
| Jun 2025 | 66.41% | - | 7.23% | 11.4% | 33.59% |
| Mar 2025 | 50.1% | - | 11.05% | 16.6% | 49.9% |
| Dec 2024 | 50.1% | - | 10.84% | 16.68% | 49.9% |
| Sep 2024 | 50.1% | - | 10.7% | 16.94% | 49.9% |